文章预览
医学评论英文版原文： Mazza R, Maher J, Hull CM. Challenges and considerations in the immunotherapy of DLL3-positive small-cell lung cancer using IL-18 armoured chimeric antigen receptor T-cells. Transl Lung Cancer Res 2024;13(3):678-683. doi: 10.21037/tlcr-23-793. 被点评研究： Jaspers JE, Khan JF, Godfrey WD, et al. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest 2023;133:e166028. 使用IL-18装备的嵌合抗原受体T细胞对DLL3阳性小细胞肺癌进行免疫治疗的挑战和注意事项 Roberta Mazza 1 , John Maher 1,2,3 , Caroline M. Hull 1 1 Leucid Bio Ltd., Guy’s Hospital, London, UK; 2 School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Hospital, London, UK; 3 Department of Immunology, Eastbourne Hospital, Eastbourne, UK 翻译：李梦超；审校：赵晋波 关键词：δ样配体3（DLL3）；小细胞肺癌（SCLC）；免疫疗法；分泌白细胞介素-1
………………………………
